Fox Chase Cancer Center News

Fox Chase Researcher Receives Funding From NCCN to Evaluate Drug in Gastric and Esophageal Cancer Patients

PHILADELPHIA (August 12, 2021) – Namrata “Neena” Vijayvergia, MD, assistant chief of Gastrointestinal Medical Oncology at Fox Chase Cancer Center, has received funding from the National Comprehensive Cancer Network (NCCN) to evaluate neratinib, also known by its brand name Nerlynx, in combination with another drug for the treatment of refractory gastric and esophageal cancer.

VIEW STORY